



Eversense[®] CGM System

THE WORLD'S FIRST AND ONLY LONG-TERM CONTINUOUS GLUCOSE MONITORING SYSTEM

Forward-looking Statements

Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding managements plans, objectives and goals for future operations, expectations for future financial or other performance, statements about the commercial launch and growth of Eversense® 365 and Eversense RPM programs, statements regarding planned initiatives, investments or marketing or other programs of Senseonics or its commercial partner, Ascensia Diabetes Care, statements regarding progress and timing of collaboration and rate of adoption or growth with respect to Eversense and any health system, or its patients and providers, or the potential to enhance patient outcomes or reduce healthcare costs or other benefits, statements regarding increasing patient access, adoption and market share, and the future growth of the CGM market, statements regarding advancing development programs and potential regulatory events, approvals and availability and the attributes of future products, features and integrations, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned” and similar expressions constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and projections about future events, and such statements are, by their nature subject to risk and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the new product launch and ongoing commercialization of the Eversense product and the expansion of the Eversense product and a new RPM solution, uncertainties inherent in the reliance on the commercialization efforts and investment of Ascensia and its commercial initiatives, uncertainties inherent in reliance on and finalizing integration and commercial terms with partners or other third parties, uncertainties in user decisions and responses to new technology or initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment, uncertainties in the development of the overall CGM market, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2024 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this presentation represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. This presentation also presents management’s goals and vision for Senseonics development programs, including without limitation the Gemini and Freedom development programs. These products are not approved by the FDA and are not subject to an IDE or other investigational approval. Plans, timing, specifications and other details of these programs are subject to change based on the factors above. The forward-looking statements in this presentation should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.

About Eversense

The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see <https://www.eversenseddiabetes.com/safety-info/>.



OUR MISSION

To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.

Senseonics is targeting the large and growing Type 1 and Type 2 diabetes patient populations with the first-and-only, long-term, convenient and accurate continuous glucose monitoring systems

Senseonics has the *first and only* fully-implantable continuous glucose monitor (CGM) that lasts for one year

The Eversense[®] 365 CGM System was recently cleared by the FDA, with commercial launch now underway

Addresses the top complaints with other CGMs including comfort, convenience and accuracy

CGMs are the fastest growing diabetes tech segment and U.S. total addressable market is more than \$20 billion

Market remains significantly underpenetrated with ~1/4 eligible U.S. T1 and T2 diabetes patients utilizing CGMs

Partnerships enable near-term market ramp-up

Exclusive worldwide distribution agreement with Ascensia Diabetes Care leverages global commercial reach and experience

Recently announced commercial development agreement with Sequel Med Tech to integrate twist AID with Eversense 365 CGM

Focused on expanding software integrations (SweetSpot and Rimidi) that enable broad health system sales

Third- and fourth-generation devices being developed in parallel

Gemini System is designed to utilize a fully implantable self-powering system (IDE filing planned by year end 2025)

Freedom System is designed with no transmitter and to enable direct communication between sensor and smart phone

Competitive moat built through robust IP portfolio

105 issued US patents, 204 issued OUS patents, 199 pending patents

Management



Timothy Goodnow, PhD
President & Chief Executive Officer



Mukul Jain, PhD
Chief Operating Officer



Francine Kaufman, M.D.
Chief Medical Officer




Rick Sullivan
Chief Financial Officer



High Growth Market

CGM Fastest Growing Diabetes Technology Segment Globally*



Estimated U.S. CGM Penetration, ~80% US Type 1 & ~35% US IT

\$20B+
Annual US Total
Addressable Market
Opportunity**

*Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and Senseonics), based upon available publicly stated guidance, historic performance, and external CGM market models & Company reports, company and analyst estimates.

**Estimated total U.S. market opportunity based on total number of U.S. people with diabetes diagnoses for which CGM is covered

Eversense CGM System Addresses Unmet Needs As

THE **FIRST** AND **ONLY**

- CGM that lasts for 12 months vs. 10-15 days
- Fully implantable 3rd generation sensor
- CGM achieves 8.8% MARD*
- Transmitter that is removable
- System with on-body vibrate alerts for hypo and hyper warnings
- System with fresh, gentle-on skin adhesive patch
- Device that does not require self-insertions
- Sensor that has approved MRI conditional labeling



Therapeutic indication for 18 yo and older.

*In the ENHANCE study, Mean Absolute Relative Difference (MARD) of 8.8% was observed in the Eversense® 365 Sensor, and MARD of 9.1% was observed in primary Sensor.

See “About Eversense” slide 2 for label and safety information.

Strong and Expanding Reimbursement

Access For Over 300 Million Lives

Broad Commercial and Medicare coverage for both Product and Procedure


In April 2025, CMS updated the 2025 physician fee schedule, providing reimbursement for a full year of usage with Eversense 365 retroactive to January 1, 2025 for all eligible Medicare beneficiaries




Eversense US Patient Profiles¹

Capturing New Users and Switching Other CGM Users

New Users by Diabetes Type



Over 3/4 of our US patients switched from other CGM solutions²



Target patient profiles

Dissatisfied with Current CGM
New to CGM
Type 1 and Type 2

Top preferred features of existing users

Accuracy
Sensor Life
Implantable Convenience

Commercial Collaboration with ASCENSIA

- Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM
- ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense® 365 and next generation product
- Senseonics to Focus Streamlined Operations on Manufacturing, Research and Development of Next Generations of Eversense® Systems
- Revenue sharing arrangement - Ascensia's share of revenue increases with volume and contract duration

Leverage ADC commercial strength with current and new products



Eversense® 365 CGM

WW Estimated Commercial Investment:
~\$60M in 2024*



- A leader in BGM with 80 YEARS of innovative diabetes care products
- Approximately \$700M in sales in over 125 countries and covering 10 million people
- Approximately 1700 employees working in 31 countries

Focus Areas:

- Build brand awareness and adoption
- Protect and grow installed base


*Current estimated investment and headcount from 2024 based on plans with ADC. Subject to risks and uncertainties

Ascensia Diabetes Care – Senseonics’ Commercial Partner



Brian Hansen

President of CGM for Ascensia Diabetes Care and former Chief Commercial Officer of Tandem Diabetes



A Better Solution for Optimal Patient Care

PATIENTS

Empowering Patients to Live a Life Uninterrupted




Longest Lasting CGM

The only CGM that lasts for a year, while traditional 10–15-day CGMs often fail early*



No More Wasted CGMs Removable smart transmitter can be taken off when needed. If the transmitter gets knocked off, simply put it back on without wasting a CGM



Alerts You Can trust

Exceptional accuracy for one year, with almost no false alerts from sleeping on your CGM at night*




Maximum Comfort

Our gentle, silicone-based adhesives are changed daily and cause almost no skin reactions

PROVIDERS

Enabling Confident Clinical Decisions



One CGM. One Year of Minimal Disruptions

The longest lasting and most dependable CGM



Exceptional Accuracy Over One Year

The most accurate CGM in the hypoglycemic range and essentially no compression lows*



Designed for Improved Quality of Life

No more frequent CGM changes and wasted sensors



Reduced calibration comparable to competitive product switches but better since no sensor reset

Eversense 365 Commercial Launch

Panel 1 (Top Left): eversense 365 Continuous Glucose Monitoring System. ONE YEAR. ONE CGM. A woman in a blue shirt is shown applying a sensor to her arm.

Panel 2 (Middle): ONE YEAR. ONE CGM. A man in a white shirt and tan pants sits in a blue armchair, pointing upwards. A television in the foreground shows a close-up of the sensor.

Panel 3 (Top Right): ONE YEAR of real-time glucose readings. Just ONE sensor. A close-up of the sensor with a 18mm scale bar. eversense 365 ONE YEAR ONE CGM.

Panel 4 (Middle Right): ONE YEAR. ONE CGM. A man in a hat and sunglasses sits in a chair. eversense 365

Panel 5 (Bottom Right): ONE YEAR CGM. 26 fewer sensor changes in your way. ONE YEAR of uninterrupted glucose readings is here. 365. A woman is shown with a child, both with sensors on their arms. eversense 365

Panel 6 (Bottom Left): Welcome to one year of real time glucose readings, uninterrupted.


Commercial Growth Driven by Eversense 365 Launch

Patient installed base increased 56% in 2024, beating target growth of 50%

DEMAND

73%


Increase in U.S.
Eversense providers
YoY



Average Monthly Leads

40%

Increase in
Direct-to-
Consumer
Leads YoY



+2X

Eversense
180

Eversense
365

CONVERSION



69%

of new patients are Type
2 users



81%

of patients switched from
Dexcom, Libre, and Medtronic

Hospital System Opportunity Overview



Multiple Potential Revenue Streams

Market Potential

- Over 1,800 Accountable Care Organizations
- 400 health systems
- ~500,000 hyperglycemic and hypoglycemic events annually resulting in hospitalization cost over \$25K per event

Short-term

- Eversense® CGM Product
- Eversense® RPM Services
- EON Care Insertion Services

Strategic Goals

- Enhance quality of care – HEDIS diabetes score improvement
- Reduce avoidable hospital admissions and emergency visits and overall cost of care
- Efficient management of chronic conditions like diabetes using SweetSpot and Rimidi software platforms
- Patient Satisfaction


Long-term Expansion Opportunities

- Outcomes-based Reimbursement for CGM+RPM solutions
- Extended RPM Services

New Strategic Partnership with Sequel Diabetes

First Automatic Insulin Delivery Pump Partnership Executed


- Commercial development agreement announced in April 2025
- Partnership to enable real-time readings from Eversense® to be received by the twiist™ pump
- Readings used in the Loop algorithm to automatically adjust insulin delivery and predict future glucose levels
- Expected launch in 2H 2025



Eversense 365 will provide the longevity, continuity, and accuracy essential for AID systems

Eversense Projected Patient Ramp

Today > 10M patients utilize CGM



Less than a 1% market share of today's CGM patients needed for profitability

PRODUCT VISION

Uniquely differentiated long-term technology solution with multiple product configurations with AID and Smart Pen integration

1 SENSOR

All Diabetes Patient Segments

NO sensor change for 1 year

NO daily calibration required

NO transmitter on body



For Type 1 and Type 2 Patients
On Demand and Continuous Monitoring

Gemini System

Autonomous Sensor Testing with Data Processing Capacity Enabling 2 Products from 1 Platform

Technology


Enhanced 365 sensor with integrated battery; updated algorithm

Use Case

Full year use with 1 sensor and 1 cal/week

Two unique products:

CGM with transmitter



Standalone therapeutic FGM without transmitter



Target

Intensively managed patients who want better control

+ All insulin-using patients

+ Non-insulin patients

Freedom System

Elimination Of Transmitter By Incorporating Bluetooth In The Sensor



Technology

Enhanced 365 sensor with integrated battery and **Bluetooth communication**; updated algorithm

Use Case

Full year use with 1 sensor and 1 cal/week

No transmitter included in the System

Direct communication between sensor and handheld


Target

Intensively managed patients who want better control

+ **All insulin-using patients**

+ **Non-insulin patients**

Portfolio Overview & Potential Catalysts

	2024	2025	2026	2027	2028
Eversense® 365 <i>World's first one-year sensor</i>	 Approval with iCGM designation	CE Approval Expected	EU Launch Expected		
Gemini <i>One-year sensor with battery for continuous and optional point-in-time reading</i>		Complete feasibility trial	Submit IDE	Commercial Launch	
Freedom <i>No transmitter included in the System. Direct communication between sensor and handheld</i>		Incorporate battery power and circuitry		Submit IDE	Commercial Launch

Planned Connectivity Updates



BGM Connectivity Direct communication with Bluetooth enabled blood glucose meters

Further Pump Integration Sensor augments pump, planning additional pump partnerships

Pump AID CGM controls pump

ONE YEAR. ONE CGM.

Thank You